Tab%252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary excretion and lack of significant renal clearance. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing * **Standard dose:** 5 mg orally once daily. * **Maximum dose:** 5 mg daily. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients under 18 years of age. ## Dose Adjustments * **Renal Impairment:** No dosage adjustment necessary (regardless of stage, including end-stage renal disease). * **Hepatic Impairment:** No dosage adjustment necessary. ## Contraindications * Hypersensitivity to linagliptin (anaphylaxis, angioedema, exfoliative skin conditions have occurred). * History of pancreatitis (use with caution). * Type 1 diabetes or diabetic ketoacidosis. ## Adverse Effects * **Common:** Nasopharyngitis, increased serum uric acid. * **Serious:** Acute pancreatitis (including fatal outcomes), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin systemic exposure, potentially reducing efficacy. Consider alternative glycemic agents if co-administration is necessary. * **Insulin/Secretagogues:** May increase the risk of hypoglycemia. A dose reduction of the secretagogue or insulin may be required. ## Monitoring * **Glycemic efficacy:** HbA1c (typically every 3 to 6 months). * **Clinical:** Assess for signs/symptoms of pancreatitis (persistent, severe abdominal pain) and severe joint pain. * **Dermatologic:** Monitor for blistering or skin erosions suggestive of bullous pemphigoid. ## Clinical Pearls * **Renal sparing:** Linagliptin is the only DPP-4 inhibitor that does not require renal dose adjustments, making it a preferred choice in patients with chronic kidney disease. * **Administration:** May be taken with or without food. * **Not for weight loss:** Unlike GLP-1 receptor agonists, linagliptin is generally weight-neutral. *** *Disclaimer: This information is for educational purposes and does not substitute for clinical judgment. Always verify current prescribing information, institutional guidelines, and manufacturer package inserts before prescribing or administering medication.*